Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM
Sponsor: Neurimmune AG
Summary
This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.
Official title: A Phase 2, Single Arm, Multicenter Study to Evaluate the Pharmacodynamics and Safety of Re-Treatment With ALXN2220 in Patients With Transthyretin Amyloid Cardiomyopathy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
35
Start Date
2025-08-28
Completion Date
2026-10-31
Last Updated
2025-12-19
Healthy Volunteers
No
Conditions
Interventions
ALXN2220
Participants will receive ALXN2220 via IV infusion.
Locations (6)
Hôpital Henri Mondor
Créteil, France
CHU de Rennes - Hôpital Pontchaillou
Rennes, France
CHU Toulouse - Hôpital Rangueil
Toulouse, France
Universitätsklinikum Heidelberg
Heidelberg, Germany
University Medical Center Groningen
Groningen, Netherlands
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Spain